NCT04914546View on ClinicalTrials.gov

A Study of LY3819469 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

November 9, 2022

Study Completion Date

November 9, 2022

Conditions
Healthy
Interventions
DRUG

LY3819469

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (5)

33014

Clinical Pharmacology of Miami, Miami

33143

Qps-Mra, Llc, Miami

78229

Endeavor Clinical Trials, San Antonio

90630

Altasciences Clinical Los Angeles, Inc, Cypress

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY